Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors-The cases of ketamine and haloperidol

Neurochemistry International

Volumn 53, Issue 1-2, 2008, Pages 45-50

  Kortekaas, Rudie ^a   Maguire, R Paul ^a   van Waarde, Aren ^a   Leenders, Klaus L ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Competition; Neuroreceptor mapping; Patlak analysis; Pharmacokinetic modeling; Positron emission tomography; Sigma receptor

Indexed keywords

1 ([4 METHOXY C 11]3,4 DIMETHOXYPHENETHYL) 4 [3 (4 FLUOROPHENYL) PROPYL]PIPERAZINE; HALOPERIDOL; KETAMINE; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG COMPETITION; HALF LIFE TIME; IMAGING; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

ALGORITHMS; ANESTHESIA; ANESTHETICS, DISSOCIATIVE; ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; EXCITATORY AMINO ACID ANTAGONISTS; HALF-LIFE; HALOPERIDOL; KETAMINE; LIGANDS; MACACA MULATTA; MALE; MODELS, STATISTICAL; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; WHOLE-BODY COUNTING;

PRIMATES;

EID: 45849124557     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2008.04.010     Document Type: Article

References (23)

1. Alper K.R., Lotsof H.S., Frenken G.M., Luciano D.J., and Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am. J. Addictions 8 (1999) 234-242
2. Bowen W.D. Sigma receptors: recent advances and new clinical potentials. Pharm. Acta Helv. 74 (2000) 211-218
3. Bowen W.D., Walker J.M., Yashar A.G., Matsumoto R.R., Walker F.O., and Lorden J.F. Altered haloperidol-sensitive sigma receptors in the genetically dystonic (dt) rat. Eur. J. Pharmacol. 147 (1988) 153-154
4. Crawford K.W., and Bowen W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62 (2002) 313-322
5. Elsinga P.H., Kawamura K., Kobayashi T., Tsukada H., Senda M., Vaalburg W., and Ishiwata K. Synthesis and evaluation of [18F]fluoroethyl SA4503 as a PET ligand for the sigma receptor. Synapse 43 (2002) 259-267
6. Elsinga P.H., Tsukada H., Harada N., Kakiuchi T., Kawamura K., Vaalburg W., Kimura Y., Kobayashi T., and Ishiwata K. Evaluation of [18F]fluorinated sigma receptor ligands in the conscious monkey brain. Synapse 52 (2004) 29-37
7. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 257 (1982) 237-274
8. Helsley S., Filipink R.A., Bowen W.D., Rabin R.A., and Winter J.C. The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus. Pharmacol. Biochem. Behav. 59 (1998) 495-503
9. Ishiwata K., Tsukada H., Kawamura K., Kimura Y., Nishiyama S., Kobayashi T., Matsuno K., and Senda M. Mapping of CNS sigma 1 receptors in the conscious monkey: preliminary PET study with [11C]-SA4503. Synapse 40 (2001) 235-237
10. Kawamura K., Elsinga P.H., Kobayashi T., Ishii S., Wang W.F., Matsuno K., Vaalburg W., and Ishiwata K. Synthesis and evaluation of C-11- and F-18-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl. Med. Biol. 30 (2003) 273-284
11. Kortekaas R., Leenders K.L., van Oostrom J.C.H., Vaalburg W., Bart J., Willemsen A.T.M., and Hendrikse N.H. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol. 57 (2005) 176-179
12. Kortekaas R., van Waarde A., Maguire R.P., Leenders K.L., and Elsinga P.H. Development of an inexpensive, low attenuation styrofoam primate chair for use in a PET scanner. J. Med. Primatol. 33 (2004) 78-82
13. Loening A.M., and Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol. Imaging 2 (2003) 131-137
14. Mach R.H., Smith C.R., Al Nabulsi I., Whirrett B.R., Childers S.R., and Wheeler K.T. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 57 (1997) 156-161
15. Mach R.H., Smith C.R., and Childers S.R. Ibogaine possesses a selective affinity for sigma 2 receptors. Life Sci. 57 (1995) L57-L62
16. Mash D.C., Kovera C.A., Pablo J., Tyndale R.F., Ervin F.D., Williams I.C., Singleton E.G., and Mayor M. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann. N. Y. Acad. Sci. 914 (2000) 394-401
17. Nelder J.A., and Mead R. A simplex method for function minimization. Comput. J. 7 (1965) 308-313
18. Nguyen E.C., McCracken K.A., Liu Y., Pouw B., and Matsumoto R.R. Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 49 (2005) 638-645
19. Øye I., Hustveit O., Maurset A., Ratti Moberg E., Paulsen O., and Skoglund L.A. The chiral forms of ketamine as probes for NMDA-receptor function in humans. In: Kameyama T., Nabeshima T., and Domino E.F. (Eds). NMDA Receptor Related Agents: Biochemistry, Pharmacology and Behavior (1991), NPP Books, Ann Arbor 381-389
20. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3 (1983) 1-7
21. Sharkey J., Glen K.A., Wolfe S., and Kuhar M.J. Cocaine binding at sigma receptors. Eur. J. Pharmacol. 149 (1988) 171-174
22. Sharp J.W. Phencyclidine (PCP) acts at sigma sites to induce c-fos gene expression. Brain Res. 758 (1997) 51-58
23. Wong D.F., Gjedde A., and Wagner Jr. H.N. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J. Cereb. Blood Flow Metab. 6 (1986) 137-146